1-20 of 390 Search Results for

pharmaceutical spending

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Article
J Health Polit Policy Law (2016) 41 (2): 157–179.
Published: 01 April 2016
... 50 percent of revenues from the North American Industry Classification System (NAICS) pharmaceutical preparation manufacturing category and comparable international firms. 1 We expect to find that the effect of additional firm-level spending on marketing and administration will result in a higher...
FIGURES
Journal Article
J Health Polit Policy Law (2022) 47 (6): 755–778.
Published: 01 December 2022
...Marc A. Rodwin Abstract This article compares the pharmaceutical pricing policies employed by public and private insurers in the United States with seven price and spending control strategies employed in the United Kingdom, France, and Germany. Differences between American and European policies...
FIGURES
Image
Published: 01 December 2022
Figure 1 Per capita spent in Germany, France, the United Kingdom, and the United States on outpatient pharmaceuticals in constant $USD, 1990–2016. Note : Because of changes in UK accounts, there is no Organization for Economic Cooperation and Development (OECD) UK spending data from 1996 More
Journal Article
J Health Polit Policy Law (2022) 47 (6): 621–628.
Published: 01 December 2022
... is the price of progress? That question is central to debates over regulating the pharmaceutical industry and managing spending on drugs. In recent years, there has been incredible scientific progress, illustrated by the rapid development of highly effective COVID-19 vaccines. The COVID story demonstrates...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 629–648.
Published: 01 December 2022
.... Our work suggests several areas for future research. First, our analysis remains agnostic on whether policies that reduce pharmaceutical spending, such as targeting launch prices, will improve social welfare. Such policies are likely to improve affordability, but their impact on innovation...
FIGURES | View All (4)
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2019) 44 (5): 765–787.
Published: 01 October 2019
...Denis G. Arnold; James L. Oakley Abstract Context: Spending on direct-to-consumer advertising (DTCA) for prescription pharmaceuticals has risen to record levels, five times as much as in 1996 in inflation-adjusted dollars. Major health care provider organizations have called for additional...
FIGURES | View All (4)
Journal Article
J Health Polit Policy Law (2005) 30 (4): 555–562.
Published: 01 August 2005
... liated with a health plan. More specifi cally, it explores how fi nancial incentives and risk-sharing schemes involving pharmaceutical spending are incorporated into the con- tractual arrangements between physicians and health plans. The empirical patterns described in the article suggest...
Journal Article
J Health Polit Policy Law (2010) 35 (6): 1057–1062.
Published: 01 December 2010
... the growth in their Books  1059   pharmaceutical spending. In the following year (2001), inspired by the Reference Drug Program in the Canadian province of British Columbia, the two states created “preferred lists of drugs for which they paid only...
Journal Article
J Health Polit Policy Law (2008) 33 (2): 225–247.
Published: 01 April 2008
... variables, among which is budget impact. Budget impact refers to the total costs that drug reimbursement and use entail with respect to one part of the health care system, pharmaceutical care, or to the entire health care system, taking into account the possible reallocation of resources across budgets...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 673–690.
Published: 01 December 2022
.... The authors examined how much of Medicaid programs' accelerated approval spending is attributable to products that have demonstrated clinical benefits versus those that have not. Their findings provide support for states' concerns that pharmaceutical companies often fail to complete their required...
FIGURES
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (1998) 23 (2): 265–290.
Published: 01 April 1998
.... Gross , D. , J. Ratner, J. Perez, and S. Glavin. 1994 . International Pharmaceutical Spending Controls: France, Germany, Sweden, and the United Kingdom. Health Care Financing Review 15 ( 3 ): 127 -140. Guertin , P. 1993 . Personal communication with Rafael Semansky on 5 March...
Journal Article
J Health Polit Policy Law (2021) 46 (1): 117–145.
Published: 01 February 2021
... Spending: Insights from Twenty-Three OECD and EU Countries .” www.oecd.org/health/health-systems/Improving-Forecasting-of-Pharmaceutical-Spending-Report.pdf (accessed August 17 , 2020 ). Parliament of the Czech Republic . 2018 . “ National Parliament Reasoned Opinion on Subsidiarity .” May...
Journal Article
J Health Polit Policy Law (2008) 33 (5): 979–1005.
Published: 01 October 2008
... in Germany (continued) Categories of Reforms Types of Reform Description C. Drug-spending 7. Reference pricing Levy of a fixed prescription charge to reference-priced drugs reforms Reduction in prices of referenced pharmaceuticals...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 815–833.
Published: 01 December 2022
...). Taken together, this body of literature strongly suggests that industry payments increase pharmaceutical spending in ways that are unlikely to improve patient outcomes. The most relevant statute with respect to physician-industry relationships is the federal AKS (Anti-Kickback Statute, 42 U.S.C...
Journal Article
J Health Polit Policy Law (2003) 28 (4): 615–658.
Published: 01 August 2003
... Times, 18 June. Gross, D., J. Ratner, J. Perez, and S. Glavin. 1994. International Pharmaceutical Spend- ing Controls: France, Germany, Sweden, and the United Kindgdom. Health Care Financing Review 15(3):127–140. Hall, P. 1986. Governing the Economy: The Politics of State Intervention...
Journal Article
J Health Polit Policy Law (2021) 46 (1): 71–92.
Published: 01 February 2021
.... They suggest the inclusion of alternative or additional indicators. For example, more complex data on pharmaceutical spending might be needed for good policy. Pharmaceutical spending is conditioned by population demographics and relevant only in relation to health outcomes, so a more holistic picture is needed...
Journal Article
J Health Polit Policy Law (1990) 15 (1): 1–67.
Published: 01 February 1990
... spending per capita accelerated after the mid-1970s in all three countries. Looking at the three major categories of health expenditures-ambulatory med- ical services, institutional medical care, and pharmaceutical goods and therapeutic appliances- the individual time patterns of Canada...
Journal Article
J Health Polit Policy Law (2005) 30 (6): 1003–1026.
Published: 01 December 2005
... care provid- ers, who have a crucial role in health care expenditure. The separation of drug prescribing and dispensing had the potential to reduce physicians’ incentive to overprescribe, but it provided few incentives for them to mini- mize pharmaceutical spending. In addition...
Journal Article
J Health Polit Policy Law (2014) 39 (2): 295–330.
Published: 01 April 2014
... an explicit motivation for lack of policy action for decades. In 1965, the Royal Commission on Health Services recommended, in effect, that policy makers wait for pharmaceutical spending to plateau before expanding Medicare to include pharmacare — a condition that never did arrive (Canada 1965 ). The focus...
Journal Article
J Health Polit Policy Law (2007) 32 (5): 895–913.
Published: 01 October 2007
...? In Monitoring the Financial Flows for Health Research 2005:Behind the Global Numbers , ed. M. A. Burke, 27 -43. Geneva: Global Forum for Health Research. ____. 2006b . Pricing Pharmaceuticals in the USA. In Excessive Medical Spending: Facing the Challenge , ed. N. J. Temple and A. Thompson, 63 -79...